Mast cells are central regulators of allergic and inflammatory responses, making them a valuable human-relevant system to study drug-induced immune activation, toxicity, and therapeutic effects. Genoskin developed a standardized human primary mast cell platform derived from CD34⁺ progenitors and validated through phenotypic and functional assays, including FcεRI- and MRGPRX2-mediated activation. The cells exhibited a mature phenotype and robust, reproducible degranulation responses across donors. Together, these results demonstrate the platform’s utility for predictive, ethical, and translational evaluation of immune safety and efficacy in drug development.

Genoskin booth #1010

We look forward to engaging in high-quality scientific discussions with experts advancing allergy and immunology research. Attendees are warmly invited to visit our booth, view our poster, and learn more about how Genoskin’s mast cell and human skin model platforms can support immune-focused research and therapeutic development.